Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

45%

5 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

6(54.5%)

Phase 4

4(36.4%)

Phase 3

1(9.1%)

11Total

Phase 2(6)

Phase 4(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT06623539Phase 2Active Not Recruiting

Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease

Role: lead

NCT04352400Phase 2Unknown

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)

Role: collaborator

NCT04784780Phase 4Unknown

Long-term Elobixibat for Chronic Constipation

Role: lead

NCT05084404Phase 2Unknown

Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease

Role: lead

NCT05165199Phase 4Unknown

Elobixibat for Chronic Constipation Without Defecation Desire

Role: lead

NCT04235205Phase 2Completed

Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease

Role: lead

NCT04118699Phase 2Unknown

Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial

Role: lead

NCT01869660Phase 2Completed

Shared Decision Making for Patients With First-admission Schizophrenia

Role: lead

NCT02331602Phase 4Unknown

Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran

Role: collaborator

NCT00190580Phase 4Completed

Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease

Role: collaborator

NCT00336947Phase 3Unknown

S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer

Role: lead

All 11 trials loaded